Oncology patient intelligence
Cansarty Health will deliver AI-powered education and support to cancer patients in Ontario and across Canada — and transform every interaction into organizational intelligence for hospitals and pharma. Launching 2027.
The evidence base
The scale of cancer in Ontario is documented, projected, and growing. The gap in patient education and support is equally well evidenced. These three data points define the opportunity Cansarty is built to address.
By 2030, Ontario will diagnose 115,306 2 new cancer patients every year and lose 37,351 2 to the disease. Every one of those patients will leave a clinical appointment with questions, fears, and decisions to make — most without adequate support. The education materials designed to help them are written above the level most people can comfortably read. 3 Every patient interaction that goes unsupported is also a data signal that disappears — a missed opportunity for the hospitals and pharma partners trying to improve care.
Three delivery channels
Cansarty will deploy through Ontario Health oncology programs, pharmaceutical partners, and directly to patients — creating a unified signal across the entire cancer care journey.
Integrated into Ontario's Regional Cancer Program workflows, Cansarty will support patients between appointments — reducing call volume, improving adherence, and surfacing real-time signals for clinical teams.
Deployed alongside specialty oncology medications in Canada, Cansarty will surface real patient decision signals — patient decision signals, initiation patterns, and emerging information needs.
For patients not yet reached through a hospital or pharma program — trusted education, peer connection, and advocacy tools. Available in English and French across Ontario.
How it will work
A continuous loop that serves the patient and informs the system — simultaneously.
A cancer patient in Ontario interacts with Cansarty through their hospital portal, pharma support program, or directly — in plain language, any time, in English or French.
Responses are grounded in Ontario Health and Health Canada approved clinical content — tailored to diagnosis, treatment stage, and patient context. Never generic.
For hospital and pharma partners, every conversation generates structured signals — concern categories, decision drivers, health literacy signals, and emerging population patterns.
Who we serve
With 97,193 new cases in Ontario alone every year — and 705,654 people living with cancer — Cansarty aligns patient needs with organizational goals across the entire cancer system.
Designed to integrate with Ontario's Regional Cancer Programs — supporting care team efficiency, surfacing real-time patient intelligence between visits, and supporting quality improvement.
Understand the real patient experience of your oncology product in the Canadian market — from initiation through adherence — with a compliant, PIPEDA-aligned signal layer.
Whether accessed through a hospital program, pharma partnership, or directly — patients receive the same trusted, compassionate, evidence-based experience. Designed with Ontario's diverse patient population in mind — including communities where access to health information and navigation support is most needed.
Features
We are building a comprehensive suite of tools for patients, clinicians, and organizational partners across Ontario and Canada. Planned for launch in 2027.
Always-on AI answering patient questions about diagnosis, treatment, and side effects — grounded in Ontario Health and Health Canada approved content, 24/7.
Real-time reporting for Ontario Health oncology programs and pharma partners — surfacing patient signals, health literacy gaps, and adherence trends as they emerge.
Designed to integrate with Ontario's Regional Cancer Program infrastructure and patient portals — minimal IT lift, maximum reach.
The platform
Ontario's cancer system is large, distributed, and highly regulated. Cansarty is being designed around Ontario Health guidelines, Canadian privacy law, and the integration requirements of Ontario's Regional Cancer Programs and 14+ cancer centres.
All patient data will be de-identified, encrypted, and processed under Canadian federal and Ontario provincial privacy legislation.
Every AI response will be built on content aligned with Ontario Health, Cancer Care Ontario, and Health Canada approved guidelines — never hallucinated.
Designed to meet Grade 6 readability standards — directly addressing the documented gap in Ontario cancer patient education materials identified across 14 provincial cancer centres.
Concept: organizational insights dashboard
Founded from experience
Cansarty was founded by a medical communications professional and cancer caregiver who turned personal experience into a structured career pivot. She completed a Master of Health Industry Administration (MHIA) in 2024, has served as a voluntary Patient Family Advisor at Ontario Health since October 2023 — contributing to the development of the Ontario Cancer Plan 6 (OCP6) — and worked as a project manager at the Toronto Central North Regional Cancer Program on regional oncology strategy and cancer screening transition.
Read the full story →95,700 Ontarians will receive a new cancer diagnosis in 2026 alone. That number is rising. Most of the questions, decisions, and moments of uncertainty that follow happen outside the clinic — Cansarty is building the infrastructure to support patients through every one of them.
Get in touch
We're in early development and actively seeking discovery conversations with Ontario Health oncology programs, Canadian pharma partners, patient advocates, and investors. Whether you want to partner, advise, or be notified at launch — we'd love to hear from you.